A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise Tolerance
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms METEORIC-HF
- Sponsors Amgen
- 06 Sep 2019 According to a Cytokinetics media release, the design of this study will be presented on 13th Sep 2019 as a poster presentation at the 23rd Annual Heart Failure Society of America (HFSA) Scientific Meeting in Philadelphia.
- 09 May 2019 According to a Cytokinetics media release, the company expects to enrollment in this study throughout 2019.
- 03 Apr 2019 Planned initiation date changed from 29 Mar 2019 to 30 Apr 2019.